Lymphedema: How Do We Diagnose and Reduce the Risk of This Dreaded Complication of Breast Cancer Treatment?

Lymphedema is an under-recognized, progressive, life-long condition estimated to impact 2-3 million people in the United States. The incidence of breast cancer related lymphedema varies greatly in the literature largely due to different measurement techniques, competing thresholds for defining lymph...

Full description

Saved in:
Bibliographic Details
Published inCurrent breast cancer reports Vol. 2; no. 1; pp. 53 - 58
Main Authors Bernas, Michael J., Askew, Robert L., Armer, Jane M., Cormier, Janice N.
Format Journal Article
LanguageEnglish
Published New York Current Science Inc 01.03.2010
Subjects
Internal Medicine
Medicine
Medicine & Public Health
Oncology
Surgical Oncology
Lymphedema
Breast cancer
Online AccessGet full text

Cover

More Information
Summary:Lymphedema is an under-recognized, progressive, life-long condition estimated to impact 2-3 million people in the United States. The incidence of breast cancer related lymphedema varies greatly in the literature largely due to different measurement techniques, competing thresholds for defining lymphedema, and variation in length of follow-up. Multiple imaging techniques have become useful for diagnosis. Lymphoscintigraphy is one of the most commonly used, as it can identify pathways of lymphatic drainage, quantify extent of dermal backflow, and help determine functional and morphologic changes in the lymphatic system. Early detection and intervention hold the greatest promise of reducing the incidence of lymphedema. Health care providers involved with cancer patients need to become more educated about lymphedema, aware of current risk-reduction practices, and familiar with methods of diagnosis and assessment, so that patients with early swelling can be referred to lymphedema treatment specialists at a time when treatment is more effective.
ISSN:1943-4588
1943-4596
DOI:10.1007/s12609-010-0009-1